Metformin vs Semaglutide
## Overview
Metformin and semaglutide are both first-line agents for type 2 diabetes in contemporary guidelines, but they work through completely different mechanisms. Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity; semaglutide is a GLP-1 receptor agonist that enhances insulin secretion and markedly reduces appetite. Both are recommended in patients with T2DM and established ASCVD or CKD, though semaglutide has direct cardiovascular outcome benefits that extend beyond glucose control.
## Mechanism of Action
Metformin: activates AMPK (AMP-activated protein kinase), primarily in hepatocytes, reducing hepatic gluconeogenesis and glucose output. Also improves peripheral insulin sensitivity, reduces fatty acid oxidation, and may modulate gut microbiome.
Semaglutide: activates GLP-1 receptors in the pancreatic beta cells (glucose-dependent insulin secretion), alpha cells (glucagon suppression), hypothalamus (satiety), and GI tract (delayed gastric emptying). Weight loss is a prominent and clinically valuable effect.
## Pharmacokinetics
Metformin: oral, ~50–60% bioavailability, renally excreted unchanged, half-life ~6 h, should be avoided in eGFR <30 mL/min/1.73m². Semaglutide: SC (weekly) or oral (daily on empty stomach), half-life ~7 days, protein-bound, not renally cleared.
## Glycemic Efficacy
Metformin: reduces HbA1c by ~1.0–1.5% as monotherapy. Semaglutide 1 mg SC: reduces HbA1c by ~1.5% and promotes ~6 kg weight loss. Semaglutide 2.4 mg (Wegovy, obesity): ~15% body weight loss. Both are highly efficacious; semaglutide is superior for weight loss.
## Cardiovascular Evidence
Metformin (UKPDS-34): reduced macrovascular events in overweight T2DM patients — historically the first agent with CV evidence in T2DM. Semaglutide (SUSTAIN-6, SELECT): 26% MACE reduction in T2DM and 20% MACE reduction in obesity without DM. Semaglutide has stronger, more recent cardiovascular outcome trial evidence.
## Safety
Metformin: lactic acidosis (rare, mainly in renal impairment), GI side effects, B12 deficiency with long-term use. Semaglutide: nausea/vomiting (especially during titration), pancreatitis (class concern), contraindicated in personal/family history of medullary thyroid cancer.
## Key Takeaways
- Metformin: first-line for T2DM, weight-neutral, cheap, proven CV benefit (UKPDS)
- Semaglutide: superior weight loss, newer and stronger CV outcome data, expensive, weekly injection
- ADA 2024: both recommended first-line; semaglutide preferred if weight loss or ASCVD/HF are primary goals
الخلاصة
Metformin remains the foundational first-line therapy for T2DM (ADA guidelines) due to its efficacy, safety record, and very low cost. Semaglutide is now co-recommended as first-line when weight loss or cardiovascular/renal risk reduction are primary goals. In practice, many patients with established ASCVD or HF benefit from semaglutide regardless of baseline HbA1c. The two drugs are frequently combined for additive glycemic and metabolic benefit.